<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457233</url>
  </required_header>
  <id_info>
    <org_study_id>31</org_study_id>
    <nct_id>NCT03457233</nct_id>
  </id_info>
  <brief_title>The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles</brief_title>
  <official_title>The Impact of Overweight and Obesity on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of ovulation cycle:

        1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG
           administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu.

        2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne
           Switzerland) is given using flexible protocol, it is given when at least one follicle
           reaches size 14 mm to prevent premature lutenization ,until the day of hCG
           administration

        3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans
           vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles
           reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of
           HCG trigger.

        4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG
           injection

        5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as
           luteal support from the day of oocytes retrieval.

        6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization.

        7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer
           .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks
           after, to confirm fetal pulsations as well as number of gestational sacs (clinical
           pregnancy).

        8. The implantation rate is calculated as the number of viable embryos divided by the
           number of transferred embryos multiplied by 100
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of ovulation cycle:

        1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG
           administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu.

        2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne
           Switzerland) is given using flexible protocol, it is given when at least one follicle
           reaches size 14 mm to prevent premature lutenization ,until the day of hCG
           administration

        3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans
           vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles
           reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of
           HCG trigger.

        4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG
           injection

        5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as
           luteal support from the day of oocytes retrieval.

        6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization.

        7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer
           .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks
           after, to confirm fetal pulsations as well as number of gestational sacs (clinical
           pregnancy).

        8. The implantation rate is calculated as the number of viable embryos divided by the
           number of transferred embryos multiplied by 100
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>4 weeks after HCG triggering</time_frame>
    <description>appearance of intrauterine gestational sac by transvaginal ultrasound</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Invitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Normal weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>18.5- 24.9 kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 25-29.9 kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI ≥ 30 kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropins</intervention_name>
    <description>1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration</description>
    <arm_group_label>Normal weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
    <other_name>Human menopausal gonadotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNRH antagonist</intervention_name>
    <description>cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration</description>
    <arm_group_label>Normal weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
    <other_name>cetrorelix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human chorionic gonadotropin Chorimon</intervention_name>
    <description>10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm</description>
    <arm_group_label>Normal weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
    <other_name>HCG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natural progesterone</intervention_name>
    <description>400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing</description>
    <arm_group_label>Normal weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
    <other_name>prontogest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  4- Poor responder according to ESHRE consensus; in which at least 2 of the following
             should be present: Advanced maternal age (≥ 40 years old) or any other risk factor A
             previous poor ovarian response (cycles cancelled or ≤ 3 oocytes with a conventional
             protocol)An abnormal ovarian reserve test (ORT); antral follicle count (AFC) &lt; 5-7
             follicles or anti-mullerian hormone (AMH) ≤0.5- 1.1 ng/ml In the absence of advanced
             maternal age or abnormal ORT, two previous episodes of poor ovarian response after
             maximal stimulation patients are also considered poor responders according to ESHRE
             consensus.

        Presence and Adequate visualization of both ovaries Uterine cavity within normal anatomy
        assessed with HSG, hysteroscopy and TVUS

        Exclusion Criteria:

        Any factor which may affect reproductive outcome other than that the patient is a poor
        responder will be excluded from the study, like:

          1. Severe male factor .

          2. Uterine factor (eg: fibroid, polyp, Ashermann, .. etc)

          3. Immunological disorder (eg: SLE, APS, … etc)

          4. Thyroid or adrenal dysfunction

          5. Neoplasia (especially: hypothalamic, pit, ovarian)

          6. Women diagnosed with PCOS according to Rotterdam criteria

          7. Hydrosalpinx that hasn't been surgically removed or ligated.

          8. Untreated hyperprolactinemia

          9. Abnormal bleeding disorder

         10. Hepatic or renal dysfunction

         11. Hypersenstivity to study medication ( GNRH antagonist)

         12. Need to take medication that can influence ovarian stimulation

         13. Endometriosis grade 3 or 4

         14. Ovarian cyst&gt; 10 cm.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Maged, MD</last_name>
    <phone>+2001005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radwa Fahmy, MD</last_name>
    <email>radwafahmi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Maged, MD</last_name>
      <phone>01005227404</phone>
      <email>prof.ahmedmaged@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

